Source comparison
Comparison: BPC-157 vs Other Prohibited Peptides Under WADA
BPC-157 S0 (Non-Approved) + S2 (Peptide Hormones) VEGF/FGF upregulation, angiogenesis, tissue repair 48–72 hours 2–4 years None. No approved therapeutic use TB-500 (Thymosin Beta-4) S2 (Peptide Hormones) Actin-binding, cell migration, wound healing 7–10 days N
This comparison does not assign a generated winner or score.
- BPC-157
- S0 (Non-Approved) + S2 (Peptide Hormones)
- VEGF/FGF upregulation, angiogenesis, tissue repair
- 48–72 hours
- 2–4 years
- None. No approved therapeutic use
- TB-500 (Thymosin Beta-4)
- S2 (Peptide Hormones)
- Actin-binding, cell migration, wound healing
- 7–10 days
- None. Not approved for human use
- IGF-1 LR3
- S2 (Peptide Hormones, Growth Factors)
- IGF-1 receptor agonism, protein synthesis
- 5–7 days
- 4 years (high severity)
- None. Synthetic analog
- CJC-1295
- S2 (Growth Hormone Releasing Hormones)
- GH secretagogue, prolonged GH elevation
- 6–8 days
- None. Not approved
- Melanotan II
- S0 (Non-Approved)
- Melanocortin receptor agonism
- 3–5 days
- None. Cosmetic use, not therapeutic
- EPO (Erythropoietin)
- Red blood cell production
- 2–4 weeks (urine)
- 4 years (high severity, intent often presumed)
- Yes. Available for specific anaemias under strict monitoring
- BPC-157 shares structural and functional similarities with TB-500 (Thymosin Beta-4), another banned peptide commonly marketed for soft tissue repair. Both peptides act through growth factor modulation and are prohibited under S2, but TB-500 has a significantly longer detection window due to its higher molecular stability and slower renal clearance. Athletes switching from TB-500 to BPC-157 hoping for reduced detection risk gain marginal advantage at best. Both peptides are detectable, both trigger identical sanctions, and neither qualifies for medical exemption. The comparison underscores a critical point: no recovery-focused peptide currently holds approved therapeutic status sufficient to justify TUE approval in competitive sport.